Plasma Calprotectin Is Predictive for Short-Term Functional Outcomes of Acute Ischemic Stroke

Frontiers in Neurology

Rongzhong Huang¹  Yongyong Li¹  Jun Zhang²  Yongping Zhu²  Zicheng Hu²  Haihua Li²  Haitao Ran³  Tingting Shang³  Xiao Yang⁴ 

[1] Department of Gerontology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China;Department of Neurology, People's Hospital of Chongqing Hechuan (PHHC), Chongqing, China;Department of Ultrasound, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China;Neuroscience Center, General Hospital of Ningxia Medical University, Yinchuan, China;

关键词: acute ischemic stroke;    biomarker;    calprotectin;    functional outcome;    inflammation;   

DOI  :  10.3389/fneur.2022.811062

来源: DOAJ

【 摘 要 】

BackgroundBlood-based prognostic biomarkers of acute ischemic stroke (AIS) are limiting. Calprotectin is suggested to be involved in directing post-stroke inflammatory conditions. However, the pathological alteration of circulating calprotectin in AIS is yet to be thoroughly elucidated. Therefore, this study aimed to investigate the levels and clinical relevance of calprotectin in AIS.MethodsThis study recruited 271 patients with AIS within 24 h since symptom onset and 145 non-stroke healthy controls (HC) from February 1, 2018, to Dec 31, 2020. Patients were followed up for 2 weeks for observation of functional outcomes, as determined by the National Institutes of Health Stroke Scale (NIHSS) and modified Rankin Scale (mRS). Plasma calprotectin concentrations were determined by ELISA.ResultsPlasma calprotectin concentrations were significantly higher in patients with AIS compared with controls [patients vs. control: median (IQR) 54.2 (39.01–99.04) vs. 50.04 (35.42–61.22), p < 0.001]. Besides, patients with poor prognosis, as defined by mRS ≥ 3, had significantly higher calprotectin levels than patients with good prognosis [poor prognosis patients vs. good prognosis patients: median (IQR) 61.99 (47.52–108) vs. 43.36 (33.39–60.2), p < 0.001]. Plasma calprotectin levels were positively associated with the disease severity of AIS, as reflected by infarction volume and NIHSS score at baseline. Furthermore, baseline calprotectin was found to be independently associated with poor prognosis [odds ratio (OR): 1.02, 95% CI: 1.01–1.03] and disease progression (OR: 1.03, 95% CI: 1.02–1.04) of AIS during a 2-week follow-up, with adjustment of possible confounding factors.ConclusionPlasma calprotectin is associated with short-term functional outcomes of AIS.

【 授权许可】

Unknown